| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
5'-O-DMT-2'-O-TBDMS-Bz-rC does not have a specific biological target as it is a chemical building block rather than a pharmacologically active compound. Its role is to serve as a protected monomer in the chemical synthesis of RNA oligonucleotides. The protecting groups are designed to be selectively removed during the synthesis process to allow for the formation of phosphodiester bonds between nucleotides.
|
|---|---|
| ln Vitro |
In vitro activity is not applicable to 5'-O-DMT-2'-O-TBDMS-Bz-rC as it is a synthetic intermediate, not a bioactive compound. Its utility is demonstrated in its ability to be incorporated into RNA oligonucleotides through standard solid-phase synthesis protocols. The compound's purity (≥98%) ensures high-quality oligonucleotide synthesis.
|
| ln Vivo |
In vivo activity is not applicable to 5'-O-DMT-2'-O-TBDMS-Bz-rC as it is a chemical reagent for research use only, not a therapeutic agent. The compound is not intended for administration to living organisms.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not performed for 5'-O-DMT-2'-O-TBDMS-Bz-rC, as it is a synthetic intermediate rather than a pharmacologically active compound. Its characterization typically involves chemical analysis methods such as HPLC, NMR, and mass spectrometry to confirm identity and purity, rather than biological assays.
|
| Cell Assay |
In vitro cellular assays are not applicable to 5'-O-DMT-2'-O-TBDMS-Bz-rC. The compound is used exclusively in chemical synthesis reactions for the production of RNA oligonucleotides, which can subsequently be used in cellular assays. The compound itself is not tested directly on cells, as it is a research chemical and not a bioactive molecule.
|
| Animal Protocol |
In vivo animal experiments are not applicable to 5'-O-DMT-2'-O-TBDMS-Bz-rC. The compound is a research chemical used in oligonucleotide synthesis and is not intended for in vivo administration. Its use is strictly limited to laboratory-based chemical synthesis and molecular biology applications.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable to 5'-O-DMT-2'-O-TBDMS-Bz-rC as it is a synthetic intermediate, not a therapeutic agent. The compound is not intended for systemic administration, and its absorption, distribution, metabolism, and excretion properties are not characterized.
|
| Toxicity/Toxicokinetics |
5'-O-DMT-2'-O-TBDMS-Bz-rC is not intended for human therapeutic use, and toxicological data are not applicable as it is a research chemical. Standard laboratory safety precautions should be followed when handling this compound, including the use of personal protective equipment and proper chemical waste disposal.
|
| Additional Infomation |
5'-O-DMT-2'-O-TBDMS-Bz-rC (CAS#: 81256-87-3) has the molecular formula C43H49N3O8Si and a molecular weight of 763.95 g/mol. Its chemical name is N-{1-[(2R,3R,4R,5R)-5-{[bis(4-methoxyphenyl)(phenyl)methoxy]methyl}-3-[(tert-butyldimethylsilyl)oxy]-4-hydroxyoxolan-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide. The compound is for research use only.
|
| Molecular Formula |
C43H49N3O8SI
|
|---|---|
| Molecular Weight |
763.95
|
| Exact Mass |
763.329
|
| CAS # |
81256-87-3
|
| PubChem CID |
11029064
|
| Appearance |
White to light yellow solid powder
|
| LogP |
7.004
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
55
|
| Complexity |
1320
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)NC(=O)C3=CC=CC=C3)COC(C4=CC=CC=C4)(C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC)O
|
| InChi Key |
AOXWVTIMEGOVNF-PKGPUZNISA-N
|
| InChi Code |
InChI=1S/C43H49N3O8Si/c1-42(2,3)55(6,7)54-38-37(47)35(53-40(38)46-27-26-36(45-41(46)49)44-39(48)29-14-10-8-11-15-29)28-52-43(30-16-12-9-13-17-30,31-18-22-33(50-4)23-19-31)32-20-24-34(51-5)25-21-32/h8-27,35,37-38,40,47H,28H2,1-7H3,(H,44,45,48,49)/t35-,37-,38-,40-/m1/s1
|
| Chemical Name |
N-[1-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-[tert-butyl(dimethyl)silyl]oxy-4-hydroxyoxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (130.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3090 mL | 6.5449 mL | 13.0899 mL | |
| 5 mM | 0.2618 mL | 1.3090 mL | 2.6180 mL | |
| 10 mM | 0.1309 mL | 0.6545 mL | 1.3090 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
